Project description
MYCN oncoprotein function in aggressive tumours
In its normal state, MYCN helps control cell cycle progression and the growth of cells. However, abnormally high levels of MYCN oncoprotein promotes aggressive tumour growth by binding to active promoters and enhancing the transcriptional activity of RNA polymerase II (RNAPII). Additionally, MYCN interacts with the exosome to protect against DNA damage and can bind and direct nascent RNAs for degradation. The ERC-funded TerSor project will investigate how RNA-bound MYCN influences transcription termination and RNA sorting, helping to suppress abnormal transcription. The project will map MYCN’s RNA-binding domains, assess the effects of RNA-binding loss in cell cultures and mouse models and examine MYCN’s role. It will also explore how MYCN and the exosome collaborate to mitigate DNA damage and manage immunogenic transcripts.
Objective
The inherent stresses arising from oncogenic transcription can be counteracted by premature termination which removes RNA polymerase II (RNAPII) from DNA and enables the degradation of aberrant nascent RNA by the nuclear exosome. When overexpressed, the MYCN oncoprotein fuels the growth of aggressive tumors by globally binding active promoters and invariably enhancing RNAPII transcription. However, I have made two key discoveries showing that the function of MYCN is not restricted to gene activation: Firstly, MYCN interacts with the exosome and prevents conflicts of RNAPII with replication forks to avert lethal DNA damage. Secondly, MYCN globally leaves promoters and directly binds nascent RNAs which are then steered to the exosome for decay. RNA bound MYCN also forms large protein complexes comprising the ARS2 transcript sorting protein, RNAPII and termination factors. These findings fundamentally expand MYCN function as they reveal that the oncoprotein exists in competing DNA- and RNA-bound states with the latter fulfilling a heretofore unknown RNA degrading role.
In TerSor, we will investigate whether RNA-bound MYCN controls termination and RNA sorting processes to counteract aberrant transcription and thereby suppress DNA damage and immune recognition in neuroblastoma cells. Firstly, we will map MYCN RNA-binding domains and test the effects of RNA-binding loss in cells and neuroblastoma mouse models. Secondly, we will explore MYCN-driven regulation of termination and RNA sorting machineries. Thirdly, we will investigate how the exosome and MYCN mitigate DNA damage and the accumulation of immunogenic transcripts. Finally, we will study the structure of MYCNs interface with exosome targeting complexes.
Collectively, we will use cutting-edge approaches to profoundly further our understanding of MYCN oncogenic function by studying how the oncoproteins newly discovered ability to bind RNA maintains the genomic integrity and immune evasion of aggressive tumors.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- natural sciencesbiological sciencesgeneticsDNA
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- natural sciencesbiological sciencesgeneticsRNA
- engineering and technologyenvironmental engineeringenergy and fuels
You need to log in or register to use this function
Keywords
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Topic(s)
Funding Scheme
HORIZON-ERC - HORIZON ERC GrantsHost institution
97070 Wuerzburg
Germany